Solmi, Marco http://orcid.org/0000-0003-4877-7233
Correll, Christoph U.
Article History
First Online: 7 September 2023
Competing interests
: M.S. declares that he has received honoraria and/or has acted as a consultant for AbbVie, Angelini, Lundbeck and Otsuka. C.U.C. declares that he has acted as a consultant and/or advisor to or has received honoraria from AbbVie, Acadia, Alkermes, Allergan, Angelini, Aristo, Biogen, Boehringer-Ingelheim, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Darnitsa, Denovo, Gedeon Richter, Hikma, Holmusk, IntraCellular Therapies, Jamjoom Pharma, Janssen and/or Johnson & Johnson, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Merck, Mindpax, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Neurelis, Newron, Noven, Novo Nordisk, Otsuka, Pharmabrain, Pharmaceutical Product Development (PPD) Biotech, Recordati, Relmada, Reviva, Rovi, Sage, Seqirus, SK Life Science, Sumitomo Pharma America, Sunovion, Sun Pharma, Supernus, Takeda, Teva, Tolmar, Vertex and Viatris, and has received grant support from Janssen and Takeda. C.U.C. also declares that he has provided expert testimony for Janssen and Otsuka and has served on data safety monitoring boards for Compass Pathways, Denovo, Lundbeck, Relmada, Reviva, Rovi, Supernus and Teva. In addition, C.U.C. declares that he has received royalties from UpToDate and holds stock options for Cardio Diagnostics, Kuleon Biosciences, LB Pharma, Mindpax and Quantic.